Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Abstract Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbocicl...

Full description

Bibliographic Details
Main Authors: Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M. Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Breast Cancer Research
Subjects:
Metastatic breast cancer
CDK4/6 inhibitors
Palbociclib
Best sequence
TREnd trial
Online Access:http://link.springer.com/article/10.1186/s13058-019-1149-5

Similar Items

Similar Items